Shattuck Labs, Inc. (STTK) Current Ratio
- Current ratio · latest quarter: Value 27.59×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 27.59× | Current assets / current liabilities. $213.27M ÷ $7.73M ≈ 27.59× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 213.27M USD | Assets, Current |
| Current obligations | 7.73M USD | Liabilities, Current |
| Cash and equivalents | 63.30M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 3.94M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $213.27M | $7.73M | $63.30M | (m) | (m) | (m) | $3.94M | (m) | 27.59× |
| 2026-03-31 | $93.75M | $4.25M | $90.42M | (m) | (m) | (m) | $1.25M | (m) | 22.06× |
| 2025-12-31 | $82.47M | $7.05M | $54.19M | (m) | (m) | (m) | $2.10M | (m) | 11.70× |
| 2025-09-30 | $90.72M | $5.34M | $42.55M | (m) | (m) | (m) | $1.16M | (m) | 17.00× |
| 2025-06-30 | $54.67M | $5.34M | $50.47M | (m) | (m) | (m) | $475.00K | (m) | 10.25× |
| 2025-03-31 | $66.40M | $7.32M | $60.90M | (m) | (m) | (m) | $1.53M | (m) | 9.08× |
| 2024-12-31 | $79.22M | $8.92M | $57.39M | (m) | (m) | (m) | $2.42M | (m) | 8.88× |
| 2024-09-30 | $98.74M | $12.40M | $43.83M | (m) | (m) | (m) | $2.93M | (m) | 7.96× |
| 2024-06-30 | $114.42M | $15.03M | $60.69M | (m) | (m) | (m) | $2.82M | (m) | 7.62× |
| 2024-03-31 | $131.08M | $14.33M | $76.00M | (m) | (m) | (m) | $2.15M | (m) | 9.15× |
| 2023-12-31 | $143.22M | $11.45M | $125.63M | (m) | (m) | (m) | $1.59M | (m) | 12.51× |
| 2023-09-30 | $112.99M | $14.06M | $40.63M | $60.44M | (m) | (m) | $2.02M | (m) | 8.04× |
| 2023-06-30 | $136.45M | $12.99M | $71.89M | $45.28M | (m) | (m) | $2.01M | (m) | 10.50× |
| 2023-03-31 | $157.84M | $16.01M | $66.04M | $69.45M | (m) | (m) | $5.13M | (m) | 9.86× |
| 2022-12-31 | $184.58M | $24.96M | $47.38M | $113.90M | (m) | (m) | $7.17M | (m) | 7.39× |
| 2022-09-30 | $201.52M | $19.14M | $39.76M | $145.36M | (m) | (m) | $3.04M | (m) | 10.53× |
| 2022-06-30 | $229.42M | $24.25M | $37.87M | $176.37M | (m) | (m) | $5.67M | (m) | 9.46× |
| 2022-03-31 | $254.99M | $16.81M | $50.74M | $188.48M | (m) | (m) | $2.59M | (m) | 15.17× |
| 2021-12-31 | $288.27M | $24.59M | $92.27M | $176.54M | (m) | (m) | $10.01M | (m) | 11.72× |
| 2021-09-30 | $301.64M | $19.84M | $85.09M | $205.12M | (m) | (m) | $3.25M | (m) | 15.21× |
| 2021-06-30 | $315.88M | $15.11M | $86.49M | $218.30M | (m) | (m) | $1.01M | (m) | 20.90× |
| 2021-03-31 | $331.08M | $17.90M | $84.73M | $236.44M | (m) | (m) | $3.00M | (m) | 18.49× |
| 2020-12-31 | $345.64M | $16.83M | $157.90M | $177.55M | (m) | (m) | $1.75M | (m) | 20.53× |
| 2020-09-30 | $142.25M | $16.48M | $128.60M | $6.34M | (m) | (m) | $1.35M | (m) | 8.63× |
| 2019-12-31 | $42.44M | $19.98M | $7.01M | $32.07M | (m) | (m) | $3.05M | (m) | 2.12× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |